Coronary Artery Disease
📧 Sign up to get email alerts when something new happens for Coronary Artery Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-12-18FDA Approved: NITROGLYCERIN — Original Application (Solaris Pharma Corporation)
FDA approved the original application (ANDA) for Nitroglycerin by Solaris Pharma Corporation, establishing a generic product indication.
-
EMA approval · 2025-12-17EMA Authorised: Rapiscan (regadenoson) — GE Healthcare AS
The European Medicines Agency authorised Rapiscan, a regadenoson-based diagnostic radiopharmaceutical from GE Healthcare AS, for use in myoc…
-
FDA approval · 2025-12-10FDA Approved: THALLOUS CHLORIDE TL 201 — Supplemental Application (Curium US LLC)
The FDA approved a supplemental application for Thallous Chloride TL 201 by Curium US LLC, updating its regulatory status for use as a radio…
-
EMA approval · 2025-11-05EMA Authorised: Rivaroxaban Viatris (previously Rivaroxaban Mylan) (rivaroxaban) — Viatris Limited
The EMA authorised Viatris Limited to market rivaroxaban (brand name Rivaroxaban Viatris), expanding access to this anticoagulant as a gener…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (BIONPHARMA INC.)
FDA approved an original application for ticagrelor from Bionpharma Inc., making a generic version of this antiplatelet medication available…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Dr. Reddys Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' original application for ticagrelor as a generic version of the antiplatelet drug, expanding access t…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a ticagrelor generic.
-
EMA approval · 2025-08-28EMA Authorised: Rivaroxaban Accord (rivaroxaban) — Accord Healthcare S.L.U.
The EMA authorised Accord Healthcare's rivaroxaban product (Rivaroxaban Accord) for multiple indications including acute coronary syndrome, …
-
FDA approval · 2025-08-01FDA Approved: CLOPIDOGREL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for clopidogrel from Amneal Pharmaceuticals LLC under the ANDA process (generic product).
-
FDA approval · 2025-07-14FDA Approved: ISOSORBIDE MONONITRATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Isosorbide Mononitrate submitted by Chartwell RX, LLC. The action approves changes included in t…
-
FDA approval · 2025-06-26FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for pravastatin sodium from Dr. Reddy's Laboratories Limited. This pertains to a generic pravastatin…
-
FDA approval · 2025-05-15FDA Approved: RIVAROXABAN — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original application for generic rivaroxaban, a direct oral anticoagulant.
-
FDA approval · 2025-05-02FDA Approved: TICAGRELOR — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' generic ticagrelor (ANDA 208576) under an original application. Ticagrelor is an antiplatelet medicati…
-
FDA approval · 2025-03-25FDA Approved: EPTIFIBATIDE — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for Eptifibatide from Sagent Pharmaceuticals.
-
FDA approval · 2025-02-24FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for pravastatin sodium from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2025-01-08FDA Approved: ISOSORBIDE DINITRATE — Supplemental Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s supplemental application for Isosorbide Dinitrate, indicating an approved modification to the generic product …
-
FDA approval · 2024-12-23FDA Approved: CARDIOGEN-82 — Supplemental Application (Bracco Diagnostics Inc)
The FDA approved a supplemental application for CardioGen-82 (rubidium chloride RB-82) submitted by Bracco Diagnostics Inc.
-
FDA approval · 2024-11-19FDA Approved: EPTIFIBATIDE — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approved a supplemental application for the generic drug eptifibatide from Slate Run Pharmaceuticals, LLC, finalizing the regulatory act…
-
FDA approval · 2024-11-04FDA Approved: PITAVASTATIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for pitavastatin calcium under ANDA205955. The approval pertains to the generic pitavastatin product…
-
FDA approval · 2024-09-27FDA Approved: FLYRCADO — Original Application (GE Healthcare Inc.)
FDA approves FLYRCADO (FLURPIRIDAZ F-18) from GE Healthcare Inc. as a PET imaging radiotracer for myocardial perfusion imaging under the Ori…
-
FDA approval · 2024-08-22FDA Approved: REGADENOSON — Original Application (Indies Pharma Jamaica Limited)
FDA approved Regadenoson under an Original Application from Indies Pharma Jamaica Limited, indicating a generic version has been approved. R…
-
FDA approval · 2024-08-16FDA Approved: TICAGRELOR — Original Application (Solco Healthcare U.S., LLC)
The FDA approved a generic ticagrelor product under an original Abbreviated New Drug Application submitted by Solco Healthcare U.S., LLC.
-
FDA approval · 2024-05-29FDA Approved: PRASUGREL — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for prasugrel from Accord Healthcare Inc., enabling a generic prasugrel product to be marketed. …
-
FDA approval · 2024-05-09FDA Approved: EPTIFIBATIDE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' original application (ANDA) for a generic version of eptifibatide (Integrilin). The approval permits …
-
FDA approval · 2024-02-16FDA Approved: NITROGLYCERIN — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approves Cosette Pharmaceuticals' generic nitroglycerin under an original ANDA.